• Publications
  • Influence
Stent thrombosis in randomized clinical trials of drug-eluting stents.
BACKGROUND Definitions of stent thrombosis that have been used in clinical trials of drug-eluting stents have been restrictive and have not been used in a uniform manner. METHODS We applied aExpand
  • 1,397
  • 43
Receiver-Operating Characteristic Analysis for Evaluating Diagnostic Tests and Predictive Models
Receiver-operating characteristic (ROC) analysis was originally developed during World War II to analyze classification accuracy in differentiating signal from noise in radar detection.1 Recently,Expand
  • 796
  • 43
  • PDF
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.
AIMS The SYMPLICITY HTN-3 randomized, blinded, sham-controlled trial confirmed the safety of renal denervation (RDN), but did not meet its primary efficacy endpoint. Prior RDN studies haveExpand
  • 363
  • 24
  • PDF
Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study.
OBJECTIVES The EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study (HRS) assessed the safety and effectiveness of the MitraClip device (Abbott Vascular, Santa Clara, California) inExpand
  • 456
  • 13
Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network
Objectives To investigate the safety and efficacy of durable polymer drug eluting stents (DES) and biodegradable polymer biolimus eluting stents (biolimus-ES). Design Network meta-analysis ofExpand
  • 213
  • 11
  • PDF
Late Loss in Lumen Diameter and Binary Restenosis for Drug-Eluting Stent Comparison
Background—Published rates of coronary restenosis have fallen below 10% in drug-eluting stent trials. Early evaluations of new stents have used continuous end points that are presumed surrogates forExpand
  • 181
  • 10
Saphenous Vein Graft Stenting and Major Adverse Cardiac Events: A Predictive Model Derived From a Pooled Analysis of 3958 Patients
Background— Treatment of saphenous vein graft (SVG) stenosis with percutaneous coronary intervention has a 15% to 20% incidence of major adverse cardiac events (MACE) within 30 days. Although MACEExpand
  • 137
  • 9
The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial.
OBJECTIVES To determine if outcomes could be further improved, we investigated an embolic protection device placed proximal to the target lesion that could provide protection before lesionExpand
  • 153
  • 8
Relationship Between the Magnitude of Reduction in Mitral Regurgitation Severity and Left Ventricular and Left Atrial Reverse Remodeling After MitraClip Therapy
Background— MitraClip has been shown to reduce mitral regurgitation (MR) severity safely but to a lesser degree than surgery. No data exist on the magnitude of MR reduction necessary to reverse leftExpand
  • 123
  • 8